% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • mikeadd Dec 2, 2011 2:20 PM Flag

    Interesting thread on pharma msg board

    This is great news and should make our jobs easier, much easier. A label change is in the offing and the fda is very receptive when results are so strong. Vanco fails due to its high recurrence rate, almost twice that of fidaxomicin

    Vanco is in trouble no doubt about that. THe study results re enforce the superiority of fida.
    Cubist has a winner in fidaxomicin

    Re: fidaxomicin



    Originally Posted by Anonymous

    To the FDA, a single subgroup analysis is not sufficient for a superiority claim in the approved product labeling. If it did not convince the FDA, it will not convince the conservative world of infectious diseases enough to make fidaxomicin first line for all CDAD infections.

    ID docs always reserve newer drugs for infections that have not responded to therapeutic standard. In CDAD, that remains vancomycin or metronidazole.

    And how many PBMs and GPOs have added fidaxomicin as a preferred agent? Are you on guidelines yet? If not--so sorry but the cheapo generic vanc and metronidazole will continue to be first line.

    You don't need to worry about infectious disease specialists. We at Optimer have quickly discovered that GI runs the C. diff show and they get what they want. ID has been almost non-existant and slow to react. My territory has taken off all because of GI. My Cubist counterpart is clueless and we will not need you much longer. I have sold hospital antibiotics for a long time and this is a walk in the park!

    08-20-2011, 06:46 PM

    Re: fidaxomicin


    hello? totally not cool post my cubist counterparts have been excellent no one wants to co promote, but don't bash them, their product or their company im happy to have them on our side. yes this has become a GI drug, but all the better. they have the ID relationships, and we will work on GI lets all sell drug, make $ , have fun and help patients....probably shouldnt be in that order but hats off to cubist


    08-21-2011, 08:08 AM

    Posts: n/a
    Re: fidaxomicin

    There are good situations and bad situations (from each company) out there when it comes to this co-promote. Most people I have talked with think this whole thing is a bit strange but it is working for now. I agree that GI is taking the lead in my territory and ID seems to have crawled into a hole to hide. We don't really need ID in most cases and even my Cubist counterpart agrees that ID has been worthless so far. As long as we get the business who cares?